Rongchang Biopharma: Vedixtumab Approved for New Indication

MetaMuskRat · 2026-03-25T01:35:53+00:00

People Financial News March 23 Report: Rongchang Biotech (688331) announced on March 23 that the company recently received a Drug Registration Certificate issued and approved by the National Medical Products Administration. The new indication approval for Vedotoxumab (code: RC48, brand name: Aidi Xi®) for the treatment of HER2 low-expressing breast cancer with liver metastasis has been approved for market application. This is the fourth approved indication for Vedotoxumab in China.

MetaMuskRat

2026-03-25 01:35:53

People’s Financial News, March 23 — Rongchang Biotech (688331) announced on March 23 that the company recently received the “Drug Registration Certificate” approved and issued by the National Medical Products Administration. The new indication for VidiXitu monoclonal antibody (code: RC48, brand name: Aidixi®) for the treatment of HER2-low expression and liver metastasis in breast cancer has been approved for market launch. This is the fourth indication approved for VidiXitu monoclonal antibody domestically.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.